Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483087 | 0.86 | MTNR1A (0.73) | NPC1MAPK1HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL21595955 | 0.86 | NPC1 (0.73) | NPC1MAPK1HSD17B10ALDH1A1TP53 | |
| SCHEMBL171846 | 0.84 | MTNR1A (0.75) | NPC1MAPK1HSD17B10ALDH1A1TP53 | |
| SCHEMBL21099911 | 0.84 | MTNR1A (0.51) | NPC1MAPK1HSD17B10ALDH1A1TP53 | |
| SCHEMBL31483051 | 0.83 | SMN1; SMN2 (0.53) | NPC1MAPK1HSD17B10ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30832634 | 0.83 | MTNR1A (0.73) | NPC1MAPK1HSD17B10ALDH1A1TP53 | |
| SCHEMBL1053081 | 0.82 | MTNR1A (0.69) | NPC1HPGDSMN1; SMN2POLBDRD2 | |
| SCHEMBL13531977 | 0.82 | RAB9A (0.55) | NPC1MAPK1HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL10389706 | 0.81 | NPC1 (0.67) | NPC1MAPK1HSD17B10ALDH1A1TP53 | |
| SCHEMBL17277318 | 0.81 | POLB (0.68) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2022098371-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | YAN MATTHEW (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021154687-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2697241-B1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20070078081-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006110157-A9 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | INPP5D, INPPL1, MTAP | NPC1 2996/4885MAPK1 4075/4885HSD17B10 4027/4885 |
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | NPC1 270/4885MAPK1 3687/4885HSD17B10 2778/4885 |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | PNP, RPIA, HPRT1 | NPC1 1885/4885MAPK1 2238/4885HSD17B10 3590/4885 |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | NPC1 1885/4885MAPK1 2238/4885HSD17B10 3590/4885 |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | PPP5C, PPP3CA, PPP4R3A | NPC1 4320/4885MAPK1 1048/4885HSD17B10 3814/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | NPC1 1885/4885MAPK1 2238/4885HSD17B10 3590/4885 |
| US-20070078081-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | NPC1 229/4885MAPK1 3630/4885HSD17B10 2717/4885 |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | TYMP, PHOSPHO1, PHPT1 | NPC1 2153/4885MAPK1 2975/4885HSD17B10 4069/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | NPC1 678/4885MAPK1 1627/4885HSD17B10 3380/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | NPC1 626/4885MAPK1 2930/4885HSD17B10 1703/4885 |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | PNP, TYMP, MTAP | NPC1 1132/4885MAPK1 1979/4885HSD17B10 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.